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Abstract
Background: Evidence syntheses, and in particular systematic reviews (SRs), have become one of the cornerstones
of evidence-based health care. The Assessment of Multiple Systematic Reviews (AMSTAR) tool has become the
most widely used tool for investigating the methodological quality of SRs and is currently undergoing revision.
The objective of this paper is to present insights, challenges and potential solutions from the point of view of a
group of assessors, while referring to earlier methodological discussions and debates with respect to AMSTAR.
Discussion: One major drawback of AMSTAR is that it relies heavily on reporting quality rather than on methodological
quality. This can be found in several items. Furthermore, it should be acknowledged that there are now new methods
and procedures that did not exist when AMSTAR was developed. For example, the note to item 1 should now refer to
the International Prospective Register of Ongoing Systematic Reviews (PROSPERO). Furthermore, item 3 should consider
the definition of hand-searching, as the process of reviewing conference proceedings using the search function (e.g. in
Microsoft Word or in a PDF file) does not meet the definition set out by the Cochrane Collaboration. Moreover, methods
for assessing the quality of the body of evidence have evolved since AMSTAR was developed and should be
incorporated into a revised AMSTAR tool.
Summary: Potential solutions are presented for each AMSTAR item with the aim of allowing a more thorough
assessment of SRs. As the AMSTAR tool is currently undergoing further development, our paper hopes to add to
preceding discussions and papers regarding this tool and stimulate further discussion.
Keywords: Systematic review, Methods, Decision making, Evidence-Based Medicine
Background
Evidence syntheses, and in particular systematic reviews
(SRs), have become one of the cornerstones of evidence-
based health care. If SRs are methodologically sound, they
are considered to provide the highest level of evidence for
medical decision-making. Over recent years, the Assess-
ment of Multiple Systematic Reviews (AMSTAR) tool has
become the most widely used tool for investigating the
methodological quality of SRs [1, 2]. It was developed
based on the Overview Quality Assessment Questionnaire
[3, 4] and the checklist by Sacks [5] and consists of 11
items, each of which is categorized into a standardized set
of four possible responses: “yes”, “no”, “can’t answer” or
“not applicable”. The items relate to a priori design, study
selection and data extraction, the literature search, grey
literature, the list of included and excluded studies, study
characteristics, critical appraisal, the formulation of con-
clusions, the combination of study results, publication bias
and conflicts of interest. The measurement properties
were recently described in a SR and found to be satis-
factory in terms of interrater reliability, validity and ap-
plicability (scoring takes between 10 and 20 minutes),
although it has also been stated that some methodological
issues are still open to discussion, such as the test–retest
reliability and whether and how an overall score should be
calculated [6]. It should also be noted that several authors
have modified or augmented the original AMSTAR tool,
for example by adding new items, splitting items, or alter-
ing the rationales for answering or scoring items [7–11].
Two recently published papers present AMSTAR from
the perspective of an assessor [12, 13]. Both papers de-
scribe challenges that the assessors faced when applying
AMSTAR to SRs and present potential solutions to these
challenges.
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The main idea of our paper is to continue the discus-
sion raised by these papers and to present another per-
spective from a different group of assessors. In doing so,
we will focus only on the evaluation of SRs of random-
ized controlled trials (RCTs) using AMSTAR.
This is an ideal time for discussion, as the AMSTAR
tool is currently undergoing further development. Accord-
ing to the developers of AMSTAR, this development will
be two-fold [14]. Firstly, a new version of AMSTAR will
improve upon the original tool. Secondly, a version of
AMSTAR will be developed for SRs of non-randomized
studies; this will be called AMSTAR-NRS. According to
the tool’s developers, AMSTAR can be applied to a wide
variety of SRs, although they recognize that its original de-
velopment only took account of SRs of RCTs that evalu-
ated treatment interventions [15].
The further development of AMSTAR is a sensible step.
Even in the first AMSTAR paper, the tool’s developers ac-
knowledged that new evidence would modify current
thinking and that an update would be inevitable [16]. Now
that AMSTAR is to be updated and further developed, it
would make sense to gather the experiences of AMSTAR
users from around the world, as these might provide im-
portant ideas that could be taken into account in the new,
updated version of the tool.
The following discussion is structured according the
order of the AMSTAR items, and each item is discussed
separately. A comparison with other comparable AMSTAR
discussion papers is included at the end of the discussion.
Discussion
1. Was an ‘a priori’ design provided? The research
question and inclusion criteria should be established
before the conduct of the review. Note: Need to refer to
a protocol, ethics approval, or pre-determined/a priori
published research objectives to score a “yes.” [17].
An a priori protocol is an important component of
SRs. The intention is to reduce the risk of bias related to
selective reporting by stating a priori hypotheses and
methods explicitly [18]. However, a thorough evaluation
should focus on discrepancies between the protocol and
the final review, which research has shown to be fairly
common [19, 20]. It is not sufficient only to refer to a
protocol, therefore, as this would primarily reflect the
quality of reporting. In addition, clarification should be
given of which aspects are included in a protocol or
publication that is published a priori.
Times have changed since the development of AMSTAR.
Some years ago, it was quite common for protocols typic-
ally only to be available for Cochrane reviews. In recent
years, there have been many efforts to increase the quantity
of systematic review protocols. It is worth mentioning the
creation of the International Prospective Register of
Ongoing Systematic Reviews (PROSPERO), which was
launched in February 2011 [21]. This allows the docu-
mentation of 22 mandatory and 18 optional items with
regard to the a priori design and conduct of a review.
At the time of writing (February 2016), approximately
10,000 records (including Cochrane protocols) can be
found in PROSPERO. It would probably make sense to
mention PROSPERO as an example under this item.
Furthermore, Preferred Reporting Items for Systematic
Review and Meta-Analysis Protocols (PRISMA-P) were
published last year [22], and SR protocols are published
by journals such as Systematic Reviews, for example.
2. Was there duplicate study selection and data
extraction? There should be at least two independent
data extractors and a consensus procedure for
disagreements should be in place. Note: 2 people do
study selection, 2 people do data extraction,
consensus process or one person checks the other’s
work. [17].
This item addresses the two critical aspects of study
selection and data extraction. Study selection should be
performed by two people independently according to
AMSTAR. It is important to bear in mind that there are
also new approaches such as “liberal accelerated study se-
lection,” in which the second reviewer reviews only the
items that were excluded by the first reviewer [23]. Erro-
neously included records can still be excluded at a later
stage. So far, this approach has been more prevalent in
rapid reviews than in SRs. However, there is no obvious
reason why this method should introduce bias into SRs.
AMSTAR provides for the possibility of one author
checking the data extracted by another. This procedure
is seen as error-prone because the quality of data extrac-
tion is not as good as if the reviewers had acted inde-
pendently [24]. However, to the best of our knowledge,
this is the only study that has investigated the issue of
double data extraction; accordingly, the evidence is very
limited. Furthermore, the reviewers’ levels of expertise
might be presumed to influence data extraction. For in-
stance, an inexperienced reviewer might check the work
of an expert in a much more lenient manner than would
be appropriate. This item will also need to be updated for
future applications, as automated (computerized) data ex-
traction is bound to emerge as an issue in systematic re-
views [25]. In such situations, a human could check the
correctness and completeness of the extracted data.
As a concluding remark, we would like to point out
that the inclusion of two different aspects (study selec-
tion and data extraction) within one item might un-
necessarily impede the application of AMSTAR in the
event that only one of the two aspects is fulfilled.
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3. Was a comprehensive literature search performed?
At least two electronic sources should be searched.
The report must include years and databases used
(e.g., Central, EMBASE, and MEDLINE). Key words
and/or MESH terms must be stated and where feasible
the search strategy should be provided. All searches
should be supplemented by consulting current contents,
reviews, textbooks, specialized registers, or experts in
the particular field of study, and by reviewing the
references in the studies found. Note: If at least 2
sources + one supplementary strategy used, select “yes”
(Cochrane register/Central counts as 2 sources; a grey
literature search counts as supplementary). [17].
For the sake of reproducibility and to ensure compre-
hensive assessment of the literature search strategy, as-
sessors should have access to details of the entire search
strategy. However, AMSTAR simply requires the report-
ing of keywords and MESH terms for the awarding of a
“yes” judgement. The full search strategy is to be set out
“where feasible” but it is not obvious what this means.
Today, it is possible in most cases to set out the full
search strategy in an online supplement or at least to
make it available upon request. As a matter of common
practice, therefore, review authors provide the full search
strategy.
Another problem centres around whether supplementary
search strategies are adequate. In our opinion, the type of
supplementary strategy used in SRs forms a critical aspect
of a comprehensive literature search. In the case of SRs of
clinical studies, for example, authors should focus their
search on clinical study registers rather than on screening
text books or dissertations. Furthermore, it should be clari-
fied that it is mandatory for review authors to review the
references in the identified studies. We therefore propose
that the note be expanded as follows: If at least 2 sources +
one adequate supplementary strategy were used, and refer-
ences of the included studies were screened, select “yes”.
Furthermore, it should be borne in mind that different
authors might have different definitions of hand-searching.
Nowadays, conference proceedings can also be reviewed
by using the search function, as most conference pro-
ceedings are available as PDF files; this falls under the
definition of hand-searching given by the Cochrane
Collaboration.
4. Was the status of publication (i.e. grey literature)
used as an inclusion criterion? The authors should
state that they searched for reports regardless of their
publication type. The authors should state whether or
not they excluded any reports (from the systematic
review), based on their publication status, language
etc. Note: If review indicates that there was a search
for “grey literature” or “unpublished literature,”
indicate “yes.” SINGLE database, dissertations,
conference proceedings, and trial registries are all
considered grey for this purpose. If searching a source
that contains both grey and non-grey, must specify that
they were searching for grey/unpublished lit. [17].
This item addresses multiple aspects of study selection:
the publication status, the publication type, and language
restrictions. Some concerns are associated with it. In order
to fulfil this item, review authors need to search for grey
literature. However, all that is required is a statement of
whether or not the publication type and language restric-
tion were used as inclusion criteria. Ignoring studies writ-
ten in languages other than English could introduce a risk
of bias. However, evidence shows that omitting non-
English articles may have only a small effect, if any, on the
conclusions of a systematic review [26, 27]. Nevertheless,
it appears to be important to bear the research objective
in mind; in other words, the preceding statement might
not apply to research areas with a high prevalence of non-
English articles and research [27, 28].
Furthermore, if review authors searched databases that
appear to contain grey literature but did not mention
this explicitly, AMSTAR recommends a “no” rating. This
seems to be a questionable choice, as it is obvious that
this item might in fact have been fulfilled. In conclusion,
this item tends to evaluate the reporting quality rather
than the methodological quality.
5. Was a list of studies (included and excluded)
provided? A list of included and excluded studies
should be provided. Note: Acceptable if the excluded
studies are referenced. If there is an electronic link to
the list but the link is dead, select “no.” [17].
This item covers the documentation of included and ex-
cluded studies. In our opinion, it would be better to split
the item. Complete documentation of excluded studies is
an important aspect that review authors seldom fulfil. This
should therefore be addressed in a single, additional item,
as most recently published SRs provide a full list of in-
cluded studies. However, we are aware that this would
yield a large number of “yes” responses for the documen-
tation of included studies and therefore to little variation
across ratings.
Another strategy for the documentation of excluded
studies is proposed by the Cochrane Collaboration. Ac-
cording to the Cochrane Handbook, the list should not
include all studies retrieved by the literature search but
should contain studies that the reader might expect to
be included [29]. In more specific terms, this means that
Cochrane review authors present studies that are eligible
at first glance but do not meet the eligibility criteria. In
addition, well-known reports will also be considered if
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they are likely to be relevant to some readers. One can
assume that this strategy introduces some subjectivity to
the documentation process, which in most cases will not
be reproducible by review assessors. We propose obliga-
tory documentation of all studies excluded after the full
text versions are evaluated. A description of other rele-
vant studies may be helpful for the reader, and this could
be presented on a voluntary basis.
6. Were the characteristics of the included studies
provided? In an aggregated form such as a table,
data from the original studies should be provided on
the participants, interventions and outcomes. The
ranges of characteristics in all the studies analyzed
e.g., age, race, sex, relevant socioeconomic data,
disease status, duration, severity, or other diseases
should be reported. Note: Acceptable if not in table
format as long as they are described as above. [17].
This item is one of the most subjective, as there is no
defined threshold for assigning a “yes” or “no” rating. In
our experience, the majority of reviews meet the mini-
mum requirements for this item, resulting in a high pro-
portion of “yes” answers.
7. Was the scientific quality of the included studies
assessed and documented? ‘A priori’ methods of
assessment should be provided (e.g., for effectiveness
studies if the author(s) chose to include only
randomized, double-blind, placebo controlled studies,
or allocation concealment as inclusion criteria); for
other types of studies alternative items will be rele-
vant. Note: Can include use of a quality scoring tool
or checklist, e.g., Jadad scale, risk of bias, sensitivity
analysis, etc., or a description of quality items, with
some kind of result for EACH study (“low” or “high”
is fine, as long as it is clear which studies scored
“low” and which scored “high”; a summary score/
range for all studies is not acceptable). [17].
We believe that this item would benefit from some
additional guidance. In our understanding, the item will
most likely reflect reporting quality if the assessors sim-
ply look at whether an assessment has been made of
the scientific quality of the included studies. The item
should therefore ask whether the methodological qual-
ity has also been adequately assessed. The response will
to some extent be subjective, as adequacy can be judged
differently by different people. This might not be as im-
portant for SRs of randomized controlled trials, where
the Cochrane Risk of Bias Tool can be used as a stand-
ard. In our opinion, the choice of the most adequate
tool is not clear in the case of non-randomized studies.
For example, the Newcastle–Ottawa Scale has been
recommended by some journals but has also been criti-
cized by others [30, 31].
It is important to add that the term “scientific quality”
could be misleading in this context. This is because
reporting quality might also be regarded as a form of sci-
entific quality despite not being the focus of this item.
8. Was the scientific quality of the included studies
used appropriately in formulating conclusions?
The results of the methodological rigor and scientific
quality should be considered in the analysis and the
conclusions of the review, and explicitly stated in
formulating recommendations. Note: Might say
something such as “the results should be interpreted
with caution due to poor quality of included
studies.” Cannot score “yes” for this question if
scored “no” for question 7. [17].
With regard to the integration of the methodological
quality of individual studies, SR authors rarely provide a
definition, or a good description, of the process of deriv-
ing conclusions from studies’ results. Different groups of
authors might draw different conclusions. To improve
the plausibility of this step, we propose not only asses-
sing the quality of individual studies but also discussing
the quality of the body of evidence. Quality of evidence
describes how confident one can be that the estimate of
an intervention’s effectiveness is true [32]. An evaluation
of the body of evidence allows a link to be drawn between
the quality of the overall evidence and the strength of the
conclusions. Multiple tools exist for assessing and charac-
terizing the quality of a body of evidence [33]. When the
quality assessment of the body of evidence is integrated
into the AMSTAR checklist, examples should be given of
existing methods, e.g. the system proposed by the Agency
for Healthcare Research and Quality (AHRQ) [34] or by
the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) Working Group [35].
9. Were the methods used to combine the findings of
studies appropriate? For the pooled results, a test
should be done to ensure the studies were combinable,
to assess their homogeneity (i.e., Chi-squared test for
homogeneity, I2). If heterogeneity exists a random
effects model should be used and/or the clinical
appropriateness of combining should be taken into
consideration (i.e., is it sensible to combine?).
Note: Indicate “yes” if they mention or describe
heterogeneity, i.e., if they explain that they cannot
pool because of heterogeneity/variability between
interventions. [17].
This item appears to be useful and easy to understand
but suffers from some ambiguities. For example, in the case
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of strong clinical or statistical heterogeneity, the problem of
heterogeneity might not be solved by using the random ef-
fects model. Readers are often faced with SRs that highlight
substantial heterogeneity between the included studies. But
how should these SRs be evaluated when the authors have
conducted a meta-analysis without discussing the appropri-
ateness of combining the studies? AMSTAR does not pro-
vide guidance for such cases. The item could therefore be
improved by requiring SR authors to state or discuss the
criteria used for qualitative and quantitative synthesis of the
body of evidence [36]. The choice of whether to conduct
qualitative or quantitative synthesis is not always an obvious
one. For example, two SRs examined the effectiveness of qi-
gong for chronic conditions in the elderly [37, 38]. Given
the similarity of the two SRs, one would expect both to
have used the same synthesis method. In fact, one SR per-
formed a qualitative synthesis, while the other performed a
quantitative synthesis without giving any rationale for this
choice. Furthermore, clinical expertise in the research topic
is required in order to evaluate a SR and especially when
judging the clinical heterogeneity of the included studies.
There may also be some obstacles to reaching a consen-
sus on the assessment of reviews without meta-analyses.
In this context, an explanation should be provided of
whether this item is relevant to all SRs or only to SRs with
a meta-analysis. Some authors provide a judgment of this
item in all cases, while others state that it is not applicable
in the case of narrative synthesis. Is it sufficient to cite
clinical heterogeneity between studies without further ex-
planation? In order to receive a score of “yes”, review
authors should assess both the clinical and the statistical
heterogeneity. Furthermore, we would like to point out
that SRs can contain more than one pooled effect meas-
ure, i.e. multiple meta-analyses. This is often the case if
more than one outcome is investigated and a meta-
analysis is performed for each outcome. In such cases, it
may be difficult to judge this item at the review level. In-
stead, it might be more appropriate to reach a judgment
at the outcome level, which would make it easier to reflect
differences in this item. For example, a SR might have ap-
plied fixed effect model meta-analysis appropriately to a
number of outcomes. It would not be appropriate, how-
ever, to apply fixed effect model meta-analysis to all out-
comes, as the best term to reflect the resulting judgment
would probably be “partly”, which is not one of the pos-
sible answers under AMSTAR. We therefore believe that
item 9 should ideally be answered at the outcome level.
This would also be in line with the Cochrane Risk of Bias
Tool or with GRADE [39].
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a
combination of graphical aids (e.g., funnel plot,
other available tests) and/or statistical tests (e.g.,
Egger regression test, Hedges-Olken). Note: If no test
values or funnel plot included, score “no”. Score
“yes” if mentions that publication bias could not be
assessed because there were fewer than 10 included
studies. [17].
In accordance with the above note, reviews with fewer
than 10 included studies should receive a “yes” rating,
provided that the authors stated that there were too few
studies for an assessment of publication bias. In such
cases, there is a high risk that reporting quality will be
assessed instead of methodological quality. SRs that have
fulfilled this item may vary substantially with respect to
the assessment of publication bias. Though the differ-
ence between 9 and 10 may in fact be small, we appreci-
ate that the AMSTAR tool provides a clearly defined
threshold. Nonetheless, the idea that publication bias
cannot be assessed due to a small number of studies
means it is worth considering “not applicable” as a pos-
sible judgment.
Furthermore, this item should be given a score of “yes”
in the case of SRs that assess the quality of evidence
using GRADE methodology [40]. One possible justifica-
tion of this judgment is that GRADE requires its users
to assess the likelihood of publication bias. However,
some review authors simply provide the GRADE Sum-
mary of Findings Table without addressing the issue of
publication bias. In such cases, we would appreciate fur-
ther guidance on how to judge this item. In our opinion,
in order to fulfil this item, SR authors ought to discuss
the efforts and methods they used to assess publication
bias even if they applied the GRADE methodology.
In addition, we propose that assessors not only
evaluate funnel plots or statistical tests but also con-
sider the search strategy and/or potential conflicts of
interest [41].
11. Was the conflict of interest included? Potential
sources of support should be clearly acknowledged
in both the systematic review and the included
studies. Note: To get a “yes,” must indicate source
of funding or support for the systematic review AND
for each of the included studies. [17]
This item clearly addresses the potential conflicts of
interest both in the review itself and in the included
studies. However, it emphasizes the sources of funding
or support, whereas readers need also to be aware of any
personal conflicts of interest. One example of personal
involvement is the inclusion of studies undertaken by a
review author. To minimize the potential for influence
in judgments, the assessment of eligibility and risk of
bias in primary studies should be carried out by an au-
thor who was not involved [42].
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Generally, this item is seldom fulfilled even in Cochrane
reviews (which are known to be of high quality). This is
not surprising, as neither PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) [43] nor
the Cochrane Handbook requires the reporting of funding
sources for trials.
We warmly welcome more-detailed assessment of con-
flicts of interest. This item should reflect the risk of bias
due to conflicts of interest instead of simply examining
whether they are reported, although we openly acknow-
ledge that this task is a highly challenging one.
Comparison with other assessors’ opinions
Recently, two other debate articles have been published
regarding AMSTAR that provide a discussion at the item
level [12, 13]. Both articles are based on the author’s ex-
periences with AMSTAR. Faggion Jr. focused on two
points in his analysis: the ability of AMSTAR to assess
the methodological quality of SRs and challenges in the
interpretation of items and their scoring guidance. He
also provided suggestions for improving the tool [12].
Burda et al. followed the same idea, while also providing
suggestions for rewording items and their scoring guid-
ance [13]. As they did this for all 11 items, the results
could also be referred to as a Burda version of AMSTAR.
In addition, they also discuss the relevance of AMSTAR
response categories.
For item 1, we placed greater emphasis on a published
protocol rather than on an explicit statement in the re-
view that review questions and inclusion criteria were
defined a priori. There is still some debate as to whether
checking someone else’s data extraction is an acceptable
method of double data extraction given the lack of evi-
dence in this field. With respect to item 2, all authors
agree that it should be made much clearer that study se-
lection and data extraction should be performed by two
people. All three publications take the same approach to
item 3. Faggion Jr. also presents a special emphasis on
hand-searching [12], while only our manuscript strictly
argues for the compulsory reporting of search strategy,
assuming that this is feasible in all cases nowadays. Item
4 definitely needs to be reworded, as stated by all three
publications, but while Faggion Jr. focuses on the number
of sources [12], Burda et al. join us in highlighting the
issue that this item is heavily reliant on reporting [13].
With respect to item 5, Faggion Jr. criticizes that this item
does not state clearly whether the list of excluded studies
should include hits from the stages of title/abstract
screening or from the stage of full text evaluation [12]. He
proposes reporting the full list of excluded studies from
both stages, which is in line with the recommendation
given by the PRISMA Statement [44]. However, a sensitive
search strategy can result in a huge number of hits. From
our point of view, we would like to question whether the
benefit of this information justifies the huge effort in-
volved in documenting the reasons for exclusion at the
title/abstract screening stage. This concurs with Burda et
al., who suggest only reporting the results of the full text
screening [13]. Again, it is our opinion and the opinion of
Burda et al. that item 6 will remain highly subjective [13],
while Faggion Jr. proposes a threshold for a minimum
amount of information [12]. In our view, this might not
be feasible, as the minimum amount of information will
probably depend on the objective of the review and the in-
cluded studies. With respect to item 7, all of the publica-
tions recognise a need for revision. As a whole, it should
be clarified that this item is about the risk of bias and that
a “yes” score can only be obtained if an appropriate tool is
selected for critical appraisal. With regard to item 8, Burda
et al. also mention the GRADE approach [13], which Fag-
gion Jr. had already mentioned in relation to item 7 [12].
Overall, all three publications arrive at a recommendation
for the use of GRADE in SRs. There is a great deal of
discussion with respect to item 9. While Faggion Jr.
highlights the problems of quantitative synthesis [12],
Burda et al. also make some points with regard to
qualitative synthesis [13]. However, our manuscript is
alone in calling for this item to be assessed at the outcome
level rather than at the review level because heterogeneity
can vary depending on the item being studied. The item
concerning publication bias (item 10) raised discussions
about the mixing methodological quality and reporting
quality, as mentioned by Faggion Jr. [12] and by our
group. This also raises the question of how this item
should be rated. In this context, reference is made to
GRADE both by Burda et al. and in our publication [13].
In general, all three author groups agree that item 11 must
be clarified (e.g. that COI should be presented for all re-
view authors), although there are differences regarding the
degree of rigour needed to obtain a “yes.”
Summary
This debate paper presents methodological reflections in
relating to AMSTAR, a validated and widely used tool for
evaluating the methodological quality of SRs. It provides
insights and challenges from the point of view of a group
of assessors, while referring to earlier methodological dis-
cussions and debates with respect to AMSTAR. Potential
solutions are presented for each AMSTAR item with the
aim of allowing a more thorough assessment of SRs.
As the AMSTAR tool is undergoing further develop-
ment, our paper hopes to add to preceding discussions
and papers regarding the AMSTAR tool and to stimulate
further discussion.
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